Boston Scientific Corp. (BSX) Tops Q3 EPS by 6c; Adjusts FY11 Outlook, Guides Q411
Boston Scientific Corp. (NYSE: BSX) reported Q3 EPS of $0.15, $0.06 better than the analyst estimate of $0.09. Revenue for the quarter came in at $1.87 billion versus the consensus estimate of $1.91 billion.
Boston Scientific Corp. sees Q4 2011 EPS of $0.13-$0.16, versus the consensus of $0.10. Boston Scientific Corp. sees Q4 2011 revenue of $1.85-$1.95 billion, versus the consensus of $1.97 billion.
Boston Scientific Corp. sees FY2011 EPS of $0.67-$0.70, versus prior guidance of $0.64-$0.70 and the consensus of $0.45. Boston Scientific Corp. sees FY2011 revenue of $7.624-$7.724 billion, versus the consensus of $7.77 billion.
Boston Scientific Corp. sees Q4 2011 EPS of $0.13-$0.16, versus the consensus of $0.10. Boston Scientific Corp. sees Q4 2011 revenue of $1.85-$1.95 billion, versus the consensus of $1.97 billion.
Boston Scientific Corp. sees FY2011 EPS of $0.67-$0.70, versus prior guidance of $0.64-$0.70 and the consensus of $0.45. Boston Scientific Corp. sees FY2011 revenue of $7.624-$7.724 billion, versus the consensus of $7.77 billion.